AZ launches Crestor co-pay card to battle Lipitor copies

Joining the growing number of drugmakers using discount cards and coupons to retain patients, AstraZeneca ($AZN) has launched a co-pay help card for its statin drug Crestor. The cholesterol remedy isn't on the verge of going off patent, as some other meds with co-pay cards are, but Lipitor, one of its biggest rivals, is.

The new card gives insured patients an $18 co-pay for Crestor, up to $50 off their current co-pays. A patient with a $75 co-pay would pay $25 with the card, for instance, while a patient with a $60 co-pay would pay $18. Uninsured patients get a $50 discount on each monthly supply for 12 months.

The Crestor discount isn't as big as Pfizer's ($PFE) new discounts on Lipitor, which give insured patients a $4 co-pay, but Crestor isn't battling directly against pharmacies touting co-pays of $4 for patients who switch to generic copies. On the other hand, Crestor may be viewed as a statin for harder-to-treat patients, but recent study data didn't show a statistically significant superiority to Lipitor as AstraZeneca had hoped. You can be sure that analysts will be keeping a close eye on prescription numbers as soon as Lipitor loses exclusivity Nov. 30.

- read the AstraZeneca release
- get more from PharmaLetter

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.